Year 2

This past year, on the advice of CDAP, we completed the recommended additional proof of concept studies with LLP2A-Ale for age related osteoporosis and other indications. These new studies have demonstrated that LLP2A-Ale can also be effective in fracture healing and osteonecrosis. In addition, we completed the requested drug stability testing of LLP2A-Ale.

At this time we are awaiting decision by CIRM/CDAP regarding continuation of our Disease Team project for the use of LLP2A-Ale for the treatment of bone diseases.